Crucell Terug naar discussie overzicht

Morphosys subsidiary sloning signs contract with pfizer + increases guidance 10 Dec

1. [verwijderd] 11 december 2010 00:34

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   pfizer contract:
   
   December 10, 2010 / 7:04 am, CET
   
   MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today the signing of a non-exclusive license and technology transfer agreement between its subsidiary Sloning BioTechnology GmbH and Pfizer. The agreement covers the installation, training and use of Sloning's technology platform Slonomics® for fabrication of highly-diverse gene and protein libraries at Pfizer's subsidiary Rinat Neuroscience Corp. in South San Francisco. The MorphoSys subsidiary will receive an upfront payment in 2010, and stands to receive annual license fees over the patent lifetime of the Slonomics technology platform. Further financial details of the agreement were not disclosed.
   
   "This significant alliance around the Slonomics technology, only weeks after we closed the acquisition of Sloning, clearly illustrates the potential value of the platform," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "This alliance with Pfizer creates immediate value for our shareholders and is just the beginning of what we expect to be a considerable return-on-investment from the combined technology platforms of MorphoSys and Sloning in the years ahead."
   
   "Rinat started using Sloning's services in 2009, and we were impressed by the diversity and quality of the libraries delivered," said Jaume Pons, PhD, Chief Scientific Officer at Pfizer's Rinat subsidiary. "We therefore decided to use this innovative technology platform further for our research and development activities."
   
   Sloning's state-of-the-art Slonomics technology enables the precise construction of protein libraries comprising defined mixtures of amino acids at pre-determined positions with unprecedented speed. The technology provides a new and flexible approach to generating optimized proteins. MorphoSys acquired Sloning BioTechnology in October 2010.
   
   
   
   About MorphoSys:
   MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visit www.morphosys.com/
   
   HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® are registered trademarks of MorphoSys AG. Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.
   
   
   
   This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
   
   
   
   For more information, please contact:
   MorphoSys AG
   Dr. Claudia Gutjahr-Löser
   Head of Corporate Communications & IR
   Tel: +49 (0) 89 / 899 27-122
   
   Mario Brkulj
   Senior Manager Corporate Communications & IR
   Tel: +49 (0) 89 / 899 27-454
   
   Jessica Kulpi
   Specialist Corporate Communications & IR
   Tel: +49 (0) 89 / 899 27-332
   
   investors@morphosys.com
   
   
   ..
2. [verwijderd] 11 december 2010 00:38

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   increase guidance + keors al 11% omhoog vandaag (toch leuk voor mij en andee volgers met een belang)December 10, 2010 / 7:05 am, CET
   
   MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today increased its financial guidance for 2010 mainly as a result of the achievement of revenues from additional commercial activities, resulting from the acquisition of Sloning BioTechnology GmbH in October 2010. MorphoSys now expects full-year revenues between EUR 91 million and EUR 94 million (from previously EUR 89 million to EUR 90 million). Correspondingly, the operating profit guidance is also increased, and expected to range between EUR 13 million and EUR 16 million (from previously EUR 7 million to EUR 9 million).
   
   About MorphoSys:
   MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visit www.morphosys.com/
   
   
   
   HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® are registered trademarks of MorphoSys.
   
   This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
   
   
   For more information, please contact:
   MorphoSys AG
   Dr. Claudia Gutjahr-Löser
   Head of Corporate Communications & IR
   Tel: +49 (0) 89 / 899 27-122
   
   Mario Brkulj
   Senior Manager Corporate Communications & IR
   Tel: +49 (0) 89 / 899 27-454
   
   Jessica Kulpi
   Specialist Corporate Communications & IR
   Tel: +49 (0) 89 / 899 27-332
   
   investors@morphosys.com
   
   ..